글로벌 간질성 폐질환 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력 : 글로벌 간질성 폐질환 치료 시장

간질성 폐질환 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에 언급된 예측 기간 동안 시장이 6.40%의 CAGR로 성장할 것으로 분석합니다.

간질성 폐질환은 폐의 폐포 주변에 염증과 흉터가 생기는 것을 특징으로 하는 많은 만성 폐질환을 말합니다. 흉터로 인해 폐의 이러한 기낭(폐포)이 확장될 수 없어 혈액으로 들어가는 산소가 줄어듭니다. 영향을 받을 수 있는 폐의 다른 부분에는 기도, 혈관 및 폐 내벽이 있습니다. 흡연 , 유전, 특정 약물 또는 의약품, 유기 또는 무기 먼지 및 특정 결합 조직 또는 콜라겐 질환이 간질성 폐질환의 원인입니다. 이 질환의 증상은 호흡 곤란, 기침, 체중 감소, 식욕 부진, 피로 및 폐 출혈입니다.

간질성 폐질환의 유병률 증가, 흡연 증가, 의료비 지출 증가, 치료 옵션 개발, 제약 회사의 연구 활동 가속화를 위한 투자 증가, 질병에 대한 인식을 확산하기 위한 정부 및 민간 기관의 이니셔티브 증가는 간질성 폐질환 치료 시장을 확대할 요인입니다.

2021~2028년 예측 기간 동안 연구 개발 활동의 증가와 임상 시험 수의 급증은 간질성 폐질환 치료 시장에 유익한 기회를 제공할 것입니다.

However, high cost of treatment, life-threatening complications associated with the interstitial lung disease such as right heart failure, high blood pressure in the lungs and respiratory failure are the factors that will hinder the market growth and will further challenge the interstitial lung disease treatment market in the forecast period mentioned above.

This interstitial lung disease treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the interstitial lung disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Interstitial Lung Disease Treatment Market Scope and Market Size

The interstitial lung disease treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment, the interstitial lung disease treatment market is segmented into antibiotics, corticosteroids, lung transplant, cytotoxic drugs, antifibrotics, pulmonary rehabilitation, oxygen therapy and others.
• On the basis of diagnosis, the interstitial lung disease treatment market is segmented into biopsy, bronchoscopy, lung function test, blood test, X-ray, CT scan and others.
• On the basis of dosage, the interstitial lung disease treatment market is segmented into tablet, injection and others.
• On the basis of route of administration, the interstitial lung disease treatment market is segmented into oral, intravenous and others.
• On the basis of end-users, the interstitial lung disease treatment market is segmented into clinic, hospital and others.

The interstitial lung disease treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Interstitial Lung Disease Treatment Market Country Level Analysis

Interstitial lung disease treatment market is analyzed and market size information is provided by the country, treatment, diagnosis, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the interstitial lung disease treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the interstitial lung disease treatment market due to the presence of major key players, high prevalence of disease and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Interstitial lung disease treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Interstitial Lung Disease Treatment Market Share Analysis

Interstitial lung disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to interstitial lung disease treatment market research.

간질성 폐질환 치료 시장 보고서에 포함된 주요 기업으로는 Sumitomo Corporation, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., Sanofi, Merck KGaA, LEO Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott, Bayer AG, Allergan, Merck Sharp & Dohme Corp., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc, Spero Therapeutics, F. Hoffmann-La Roche Ltd., Mylan NV, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 별도로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-66540